Dabrafenib (D) and trametinib (T) plus spartalizumab (S) in patients (pts) with previously untreated BRAF V600-mutant unresectable or metastatic melanoma: Three-year overall survival (OS) data from the randomized part 3 of the phase III COMBI-i trial
Authors
Dummer, R.Long, G. V.
Tawbi, H. A.
Flaherty, K.
Ascierto, P. A.
Nathan, P. D.
Rutkowski, P.
Leonov, O.
Mandala, M.
Lorigan, Paul C
Ferrucci, P. F.
Grob, J. J.
Meyer, N.
Gogas, H.
Stroyakovskiy, D.
Arance, A. M.
Pakhle, N.
Waters, S.
Ribas, A.
Schadendorf, D.
Affiliation
Universitäts Spital Zürich, Zurich, Switzerland;Issue Date
2022
Metadata
Show full item recordCitation
Dummer R, Long GV, Tawbi HA, Flaherty K, Ascierto PA, Nathan PD, et al. Dabrafenib (D) and trametinib (T) plus spartalizumab (S) in patients (pts) with previously untreated BRAF V600-mutant unresectable or metastatic melanoma: Three-year overall survival (OS) data from the randomized part 3 of the phase III COMBI-i trial. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680302346.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2022.40.16_suppl.9527Additional Links
https://dx.doi.org/10.1200/JCO.2022.40.16_suppl.9527Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2022.40.16_suppl.9527